Skip directly to content

Vyndaqel® ▼ (Tafamidis)

What is Vyndaqel® (Tafamidis) and what is it used for?

Vyndaqel contains the active substance tafamidis. It is available as a capsule.

Vyndaqel is a medicine which treats a rare disease called Transthyretin (TTR) amyloid polyneuropathy, also known as TTR familial amyloid polyneuropathy (TTR-FAP). TTR amyloid polyneuropathy is caused by a protein called TTR that does not work properly. TTR is an important protein that carries other substances, such as hormones, through the body.

In patients with this disease, TTR breaks up and may form fibres called amyloid. Amyloid can build up around your nerves and in other places in your body, preventing them from working normally. Eventually, the amyloid causes the symptoms of this disease.

Vyndaqel, can prevent TTR from breaking up and forming amyloid deposits. This medicine is used to treat adult patients with this disease whose nerves have been affected (people with symptomatic polyneuropathy).

The medicine can only be obtained with a prescription.

 

Reference information
 
  • The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in London. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See what guidance they offer about Vyndaqel.
  • If you would like to see the Patient Information Leaflet or Summary of Product Characteristics for Vyndaqel these can be found at the electronic Medicines Compendium (eMC).

 

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

PP-VYN-GBR-0020 / Oct 2017